Cargando…
Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a hypercoagulable status. There is limited knowledge regarding the dynamic changes in coagulation factors among COVID-19 patients on nafamostat mesylate, a potential therapeutic anticoagulant for COVID-19. Fir...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486975/ https://www.ncbi.nlm.nih.gov/pubmed/32920751 http://dx.doi.org/10.1007/s11239-020-02275-5 |
_version_ | 1783581413743788032 |
---|---|
author | Osawa, Itsuki Okamoto, Koh Ikeda, Mahoko Otani, Amato Wakimoto, Yuji Yamashita, Marie Shinohara, Takayuki Kanno, Yoshiaki Jubishi, Daisuke Kurano, Makoto Harada, Sohei Okugawa, Shu Yatomi, Yutaka Moriya, Kyoji |
author_facet | Osawa, Itsuki Okamoto, Koh Ikeda, Mahoko Otani, Amato Wakimoto, Yuji Yamashita, Marie Shinohara, Takayuki Kanno, Yoshiaki Jubishi, Daisuke Kurano, Makoto Harada, Sohei Okugawa, Shu Yatomi, Yutaka Moriya, Kyoji |
author_sort | Osawa, Itsuki |
collection | PubMed |
description | Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a hypercoagulable status. There is limited knowledge regarding the dynamic changes in coagulation factors among COVID-19 patients on nafamostat mesylate, a potential therapeutic anticoagulant for COVID-19. First, we retrospectively conducted a cluster analysis based on clinical characteristics on admission to identify latent subgroups among fifteen patients with COVID-19 on nafamostat mesylate at the University of Tokyo Hospital, Japan, between April 6 and May 31, 2020. Next, we delineated the characteristics of all patients as well as COVID-19-patient subgroups and compared dynamic changes in coagulation factors among each subgroup. The subsequent dynamic changes in fibrinogen and D-dimer levels were presented graphically. All COVID-19 patients were classified into three subgroups: clusters A, B, and C, representing low, intermediate, and high risk of poor outcomes, respectively. All patients were alive 30 days from symptom onset. No patient in cluster A required mechanical ventilation; however, all patients in cluster C required mechanical ventilation, and half of them were treated with venovenous extracorporeal membrane oxygenation. All patients in cluster A maintained low D-dimer levels, but some critical patients in clusters B and C showed dynamic changes in fibrinogen and D-dimer levels. Although the potential of nafamostat mesylate needs to be evaluated in randomized clinical trials, admission characteristics of patients with COVID-19 could predict subsequent coagulopathy. |
format | Online Article Text |
id | pubmed-7486975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-74869752020-09-14 Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate Osawa, Itsuki Okamoto, Koh Ikeda, Mahoko Otani, Amato Wakimoto, Yuji Yamashita, Marie Shinohara, Takayuki Kanno, Yoshiaki Jubishi, Daisuke Kurano, Makoto Harada, Sohei Okugawa, Shu Yatomi, Yutaka Moriya, Kyoji J Thromb Thrombolysis Article Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a hypercoagulable status. There is limited knowledge regarding the dynamic changes in coagulation factors among COVID-19 patients on nafamostat mesylate, a potential therapeutic anticoagulant for COVID-19. First, we retrospectively conducted a cluster analysis based on clinical characteristics on admission to identify latent subgroups among fifteen patients with COVID-19 on nafamostat mesylate at the University of Tokyo Hospital, Japan, between April 6 and May 31, 2020. Next, we delineated the characteristics of all patients as well as COVID-19-patient subgroups and compared dynamic changes in coagulation factors among each subgroup. The subsequent dynamic changes in fibrinogen and D-dimer levels were presented graphically. All COVID-19 patients were classified into three subgroups: clusters A, B, and C, representing low, intermediate, and high risk of poor outcomes, respectively. All patients were alive 30 days from symptom onset. No patient in cluster A required mechanical ventilation; however, all patients in cluster C required mechanical ventilation, and half of them were treated with venovenous extracorporeal membrane oxygenation. All patients in cluster A maintained low D-dimer levels, but some critical patients in clusters B and C showed dynamic changes in fibrinogen and D-dimer levels. Although the potential of nafamostat mesylate needs to be evaluated in randomized clinical trials, admission characteristics of patients with COVID-19 could predict subsequent coagulopathy. Springer US 2020-09-12 2021 /pmc/articles/PMC7486975/ /pubmed/32920751 http://dx.doi.org/10.1007/s11239-020-02275-5 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Osawa, Itsuki Okamoto, Koh Ikeda, Mahoko Otani, Amato Wakimoto, Yuji Yamashita, Marie Shinohara, Takayuki Kanno, Yoshiaki Jubishi, Daisuke Kurano, Makoto Harada, Sohei Okugawa, Shu Yatomi, Yutaka Moriya, Kyoji Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate |
title | Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate |
title_full | Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate |
title_fullStr | Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate |
title_full_unstemmed | Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate |
title_short | Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate |
title_sort | dynamic changes in fibrinogen and d-dimer levels in covid-19 patients on nafamostat mesylate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486975/ https://www.ncbi.nlm.nih.gov/pubmed/32920751 http://dx.doi.org/10.1007/s11239-020-02275-5 |
work_keys_str_mv | AT osawaitsuki dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT okamotokoh dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT ikedamahoko dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT otaniamato dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT wakimotoyuji dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT yamashitamarie dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT shinoharatakayuki dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT kannoyoshiaki dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT jubishidaisuke dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT kuranomakoto dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT haradasohei dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT okugawashu dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT yatomiyutaka dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate AT moriyakyoji dynamicchangesinfibrinogenandddimerlevelsincovid19patientsonnafamostatmesylate |